4D Molecular Therapeutics (FDMT) to Release Earnings on Thursday

Key Points

• 4D Molecular Therapeutics is set to announce its Q2 2025 earnings on August 14th, with anticipated earnings of ($0.69) per share and revenue of $0.52 million.
• Last reported earnings showed a loss of ($0.86) per share, missing analyst expectations, while analysts forecast $-3 EPS for both the current and next fiscal years.
• Analyst ratings are mixed, with seven buy ratings and a consensus target price of $29.56, despite recent downward adjustments from firms like Goldman Sachs and Barclays.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Thursday, August 14th. Analysts expect the company to announce earnings of ($0.69) per share and revenue of $0.52 million for the quarter.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.02). 4D Molecular Therapeutics had a negative return on equity of 33.26% and a negative net margin of 767,126.06%. On average, analysts expect 4D Molecular Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

4D Molecular Therapeutics Stock Down 5.3%

NASDAQ FDMT opened at $5.73 on Thursday. The company has a 50-day moving average price of $4.34 and a 200-day moving average price of $4.06. 4D Molecular Therapeutics has a 52 week low of $2.23 and a 52 week high of $17.41. The firm has a market capitalization of $265.47 million, a P/E ratio of -1.80 and a beta of 2.83.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on FDMT shares. Chardan Capital reaffirmed a "buy" rating and set a $25.00 price objective on shares of 4D Molecular Therapeutics in a research report on Friday, August 1st. The Goldman Sachs Group dropped their price target on 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Barclays reduced their price objective on shares of 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating on the stock in a research report on Friday, May 9th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research note on Tuesday, July 29th. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, 4D Molecular Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $29.56.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Dynamic Technology Lab Private Ltd bought a new position in shares of 4D Molecular Therapeutics during the first quarter valued at approximately $39,000. AQR Capital Management LLC bought a new position in 4D Molecular Therapeutics in the first quarter worth approximately $46,000. Finally, Millennium Management LLC lifted its holdings in 4D Molecular Therapeutics by 15.0% during the first quarter. Millennium Management LLC now owns 1,633,987 shares of the company's stock worth $5,278,000 after buying an additional 213,264 shares during the period. 99.27% of the stock is owned by hedge funds and other institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.